Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.
Also called NCT04591392
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 250 participants
- Sponsor
- atHeart Medical
- Registry
-
NCT04591392
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, France, Switzerland
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04591392. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-12 (actual); primary completion 2027-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
- Acronym
- ASCENT ASD
- Condition
- Heart Septal Defect
- Condition
- Heart Septal Defects, Atrial
- Condition
- Heart Defects, Congenital
- Condition
- Cardiovascular Abnormalities
- Condition
- Cardiovascular Diseases
- Condition
- Heart Diseases
- Condition
- Congenital Abnormalities
- Intervention (Device)
- reSept ASD Occluder
- Lead sponsor
- atHeart Medical
Record details
- Record id
cardio:ct-nct04591392- Content hash
f2b5b76708875060cda3bf32c02b7c317f328dfe32bc0bbde4efc14a717bd011